儿童和青少年脑和脊柱肿瘤治疗相关改变的诊断:使用MRI和[18 F]FET PET进行成本-效果分析。

IF 7.6 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Jurij Rosen, Jan-Michael Werner, Garry S Ceccon, Elena K Rosen, Michael M Wollring, Isabelle Stetter, Philipp Lohmann, Felix M Mottaghy, Lisbeth Marner, Ian Law, Gereon R Fink, Karl-Josef Langen, Norbert Galldiks
{"title":"儿童和青少年脑和脊柱肿瘤治疗相关改变的诊断:使用MRI和[18 F]FET PET进行成本-效果分析。","authors":"Jurij Rosen, Jan-Michael Werner, Garry S Ceccon, Elena K Rosen, Michael M Wollring, Isabelle Stetter, Philipp Lohmann, Felix M Mottaghy, Lisbeth Marner, Ian Law, Gereon R Fink, Karl-Josef Langen, Norbert Galldiks","doi":"10.1007/s00259-025-07377-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>PET using the radiolabeled amino acid O-(2-[<sup>18</sup>F]-fluoroethyl)-L-tyrosine ([<sup>18</sup>F]FET) has considerable clinical value for follow-up evaluation of central nervous system tumors in children and adolescents. As medical procedures must be justified socio-economically, we determined cost-effectiveness of [<sup>18</sup>F]FET PET for identification of treatment-related changes.</p><p><strong>Methods: </strong>We analyzed clinical data from two different studies that assessed the value of FET PET to differentiate between brain and spinal tumor relapse and treatment-related changes in children and adolescents. Cost calculation was based on the German statutory health insurance system perspective. Due to subtle differences in the diagnostic approach of the studies, two separate clinical scenarios including 80 patients with 105 lesions were considered: Decision tree model 1 determined cost-effectiveness of simultaneous [<sup>18</sup>F]FET PET and MRI in comparison to MRI alone to identify treatment-related changes. Decision tree model 2 determined cost-effectiveness of [<sup>18</sup>F]FET PET alone to identify treatment-related changes when routine MRI findings were suspicious for tumor relapse. Deterministic and probabilistic sensitivity analyses tested the robustness of the results.</p><p><strong>Results: </strong>Model 1 revealed that the rate of identified treatment-related changes increased by 52% when adding [<sup>18</sup>F]FET PET to MRI, resulting in costs of €3,314.51 for each additional correctly identified lesion with treatment-related changes by [<sup>18</sup>F]FET PET that MRI would have misclassified. Model 2 revealed that [<sup>18</sup>F]FET PET correctly identified treatment-related changes in 90% of lesions when routine MRI findings were suspicious for tumor relapse, resulting in costs of €1,740.37 for each lesion.</p><p><strong>Conclusion: </strong>Integrating [<sup>18</sup>F]FET PET in the follow-up of in children and adolescents with brain and spinal tumor may help improving patient care at acceptable costs.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"4616-4626"},"PeriodicalIF":7.6000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12491346/pdf/","citationCount":"0","resultStr":"{\"title\":\"Diagnosis of treatment-related changes in children and adolescents with brain and spinal tumors: a cost-effectiveness analysis using MRI and [18 F]FET PET.\",\"authors\":\"Jurij Rosen, Jan-Michael Werner, Garry S Ceccon, Elena K Rosen, Michael M Wollring, Isabelle Stetter, Philipp Lohmann, Felix M Mottaghy, Lisbeth Marner, Ian Law, Gereon R Fink, Karl-Josef Langen, Norbert Galldiks\",\"doi\":\"10.1007/s00259-025-07377-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>PET using the radiolabeled amino acid O-(2-[<sup>18</sup>F]-fluoroethyl)-L-tyrosine ([<sup>18</sup>F]FET) has considerable clinical value for follow-up evaluation of central nervous system tumors in children and adolescents. As medical procedures must be justified socio-economically, we determined cost-effectiveness of [<sup>18</sup>F]FET PET for identification of treatment-related changes.</p><p><strong>Methods: </strong>We analyzed clinical data from two different studies that assessed the value of FET PET to differentiate between brain and spinal tumor relapse and treatment-related changes in children and adolescents. Cost calculation was based on the German statutory health insurance system perspective. Due to subtle differences in the diagnostic approach of the studies, two separate clinical scenarios including 80 patients with 105 lesions were considered: Decision tree model 1 determined cost-effectiveness of simultaneous [<sup>18</sup>F]FET PET and MRI in comparison to MRI alone to identify treatment-related changes. Decision tree model 2 determined cost-effectiveness of [<sup>18</sup>F]FET PET alone to identify treatment-related changes when routine MRI findings were suspicious for tumor relapse. Deterministic and probabilistic sensitivity analyses tested the robustness of the results.</p><p><strong>Results: </strong>Model 1 revealed that the rate of identified treatment-related changes increased by 52% when adding [<sup>18</sup>F]FET PET to MRI, resulting in costs of €3,314.51 for each additional correctly identified lesion with treatment-related changes by [<sup>18</sup>F]FET PET that MRI would have misclassified. Model 2 revealed that [<sup>18</sup>F]FET PET correctly identified treatment-related changes in 90% of lesions when routine MRI findings were suspicious for tumor relapse, resulting in costs of €1,740.37 for each lesion.</p><p><strong>Conclusion: </strong>Integrating [<sup>18</sup>F]FET PET in the follow-up of in children and adolescents with brain and spinal tumor may help improving patient care at acceptable costs.</p>\",\"PeriodicalId\":11909,\"journal\":{\"name\":\"European Journal of Nuclear Medicine and Molecular Imaging\",\"volume\":\" \",\"pages\":\"4616-4626\"},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12491346/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Nuclear Medicine and Molecular Imaging\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00259-025-07377-x\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Nuclear Medicine and Molecular Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00259-025-07377-x","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/4 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

摘要

目的:PET采用放射性标记氨基酸O-(2-[18F]-氟乙基)- l -酪氨酸([18F]FET)对儿童青少年中枢神经系统肿瘤的随访评价具有相当的临床价值。由于医疗程序必须在社会经济上合理,我们确定了[18F]FET PET用于识别治疗相关变化的成本效益。方法:我们分析了两项不同研究的临床数据,评估了FET PET在区分儿童和青少年脑和脊柱肿瘤复发和治疗相关变化方面的价值。成本计算是基于德国法定健康保险制度的观点。由于两项研究的诊断方法存在细微差异,我们考虑了两种独立的临床情景,包括80例患者105个病变:决策树模型1确定了同时使用[18F]FET PET和MRI与单独使用MRI相比的成本-效果,以确定治疗相关的变化。决策树模型2确定了在常规MRI检查结果怀疑肿瘤复发时,单独使用FET PET识别治疗相关变化的成本-效果[18F]。确定性和概率敏感性分析检验了结果的稳健性。结果:模型1显示,当将[18F]FET PET添加到MRI时,识别出的治疗相关变化的比率增加了52%,导致每增加一个正确识别出MRI可能错误分类的具有[18F]FET PET治疗相关变化的病变的成本为3,314.51欧元。模型2显示[18F],当常规MRI检查结果怀疑肿瘤复发时,FET PET正确识别了90%病变的治疗相关变化,导致每个病变的成本为1,740.37欧元。结论:将[18F]FET PET整合到儿童和青少年脑脊部肿瘤的随访中,可以在可接受的成本下改善患者的护理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Diagnosis of treatment-related changes in children and adolescents with brain and spinal tumors: a cost-effectiveness analysis using MRI and [18 F]FET PET.

Diagnosis of treatment-related changes in children and adolescents with brain and spinal tumors: a cost-effectiveness analysis using MRI and [18 F]FET PET.

Diagnosis of treatment-related changes in children and adolescents with brain and spinal tumors: a cost-effectiveness analysis using MRI and [18 F]FET PET.

Diagnosis of treatment-related changes in children and adolescents with brain and spinal tumors: a cost-effectiveness analysis using MRI and [18 F]FET PET.

Purpose: PET using the radiolabeled amino acid O-(2-[18F]-fluoroethyl)-L-tyrosine ([18F]FET) has considerable clinical value for follow-up evaluation of central nervous system tumors in children and adolescents. As medical procedures must be justified socio-economically, we determined cost-effectiveness of [18F]FET PET for identification of treatment-related changes.

Methods: We analyzed clinical data from two different studies that assessed the value of FET PET to differentiate between brain and spinal tumor relapse and treatment-related changes in children and adolescents. Cost calculation was based on the German statutory health insurance system perspective. Due to subtle differences in the diagnostic approach of the studies, two separate clinical scenarios including 80 patients with 105 lesions were considered: Decision tree model 1 determined cost-effectiveness of simultaneous [18F]FET PET and MRI in comparison to MRI alone to identify treatment-related changes. Decision tree model 2 determined cost-effectiveness of [18F]FET PET alone to identify treatment-related changes when routine MRI findings were suspicious for tumor relapse. Deterministic and probabilistic sensitivity analyses tested the robustness of the results.

Results: Model 1 revealed that the rate of identified treatment-related changes increased by 52% when adding [18F]FET PET to MRI, resulting in costs of €3,314.51 for each additional correctly identified lesion with treatment-related changes by [18F]FET PET that MRI would have misclassified. Model 2 revealed that [18F]FET PET correctly identified treatment-related changes in 90% of lesions when routine MRI findings were suspicious for tumor relapse, resulting in costs of €1,740.37 for each lesion.

Conclusion: Integrating [18F]FET PET in the follow-up of in children and adolescents with brain and spinal tumor may help improving patient care at acceptable costs.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
15.60
自引率
9.90%
发文量
392
审稿时长
3 months
期刊介绍: The European Journal of Nuclear Medicine and Molecular Imaging serves as a platform for the exchange of clinical and scientific information within nuclear medicine and related professions. It welcomes international submissions from professionals involved in the functional, metabolic, and molecular investigation of diseases. The journal's coverage spans physics, dosimetry, radiation biology, radiochemistry, and pharmacy, providing high-quality peer review by experts in the field. Known for highly cited and downloaded articles, it ensures global visibility for research work and is part of the EJNMMI journal family.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信